How to Get Wegovy Prescribed: The 2026 Eligibility Criteria, Insurance Pathways, and Alternative Routes When Coverage Fails

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires BMI ≥30 or BMI ≥27 with one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea) under FDA labeling
• About 68% of commercial insurance plans cover Wegovy with prior authorization as of 2026, but average out-of-pocket cost without coverage is $1,349 per month
• Telehealth platforms can prescribe Wegovy in all 50 states if you meet clinical criteria, with visits typically completed in 15 to 30 minutes
• When insurance denies Wegovy, compounded semaglutide (the same active ingredient) costs $297 to $450 per month and doesn't require prior authorization

Direct answer (40-60 words)

To get Wegovy prescribed, you need BMI ≥30 or BMI ≥27 with a weight-related health condition, a consultation with a licensed provider (in-person or telehealth), and either insurance approval through prior authorization or self-pay access. The process takes 24 hours to 14 days depending on your insurance pathway.

Table of contents

1. The FDA eligibility criteria: who qualifies for Wegovy
2. The three pathways to get a prescription
3. The prior authorization process: what insurance actually requires
4. Why most denials happen and the two-step appeal protocol
5. Telehealth vs in-person: which gets you prescribed faster
6. What happens during the prescribing visit
7. The cost breakdown: insurance vs savings programs vs compounded alternatives
8. What most articles get wrong about BMI requirements
9. When you don't qualify and what to do instead
10. The compounded semaglutide alternative pathway
11. State-specific restrictions you need to know
12. FAQ

The FDA eligibility criteria: who qualifies for Wegovy

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 for chronic weight management. The label specifies two qualifying pathways:

Pathway 1: BMI ≥30 You qualify if your body mass index is 30 or higher, regardless of other health conditions. No additional comorbidities required.

Pathway 2: BMI ≥27 with at least one weight-related comorbidity You qualify if your BMI is between 27 and 29.9 AND you have at least one of these conditions:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

The FDA label does not include PCOS, prediabetes, or fatty liver disease as qualifying comorbidities, though some providers use clinical judgment to prescribe off-label for these conditions.

Age requirements: Wegovy is FDA-approved for adults 18 and older. In December 2022, the FDA extended approval to adolescents ages 12 to 17 with BMI ≥95th percentile for age and sex. Pediatric prescribing requires additional documentation and is less commonly covered by insurance.

Contraindications (you do NOT qualify if):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy within 2 months
• History of severe allergic reaction to semaglutide
• Active pancreatitis

The contraindication list is short. Most patients who meet BMI criteria and don't have the specific thyroid cancer history qualify medically.

The three pathways to get a prescription

Pathway 1: Traditional in-person provider

Schedule an appointment with your primary care physician, endocrinologist, or obesity medicine specialist. The visit includes:

• Weight and height measurement
• Review of medical history and current medications
• Discussion of weight-loss goals and previous attempts
• Blood pressure check
• Possibly lab work (A1C, lipid panel, TSH)

The provider writes the prescription and sends it to your pharmacy. You then navigate insurance prior authorization (see section below).

Timeline: 1 to 4 weeks from appointment request to prescription in hand, depending on appointment availability and prior authorization speed.

Pathway 2: Telehealth platform (FormBlends, others)

Complete an online intake form with medical history, current weight, height, and photos. A licensed provider in your state reviews your information and conducts a video or asynchronous consultation. If you qualify, the prescription is sent electronically to a pharmacy (brand Wegovy if insurance covers it, or compounded semaglutide if paying out-of-pocket).

Timeline: 24 to 72 hours from intake to prescription for most platforms. No prior authorization wait if using compounded medication.

Pathway 3: Employer or health system weight-management program

Some large employers and integrated health systems (Kaiser, Geisinger, Cleveland Clinic) offer structured weight-management programs that include GLP-1 medications. These programs typically require:

• Enrollment in a 12 to 16-week program with dietitian support
• Attendance at group or individual counseling sessions
• Demonstrated adherence to lifestyle modifications before medication is prescribed

Timeline: 4 to 12 weeks from enrollment to prescription, as medication is often withheld until you complete initial program phases.

The fastest pathway for most patients is telehealth. The pathway with highest insurance approval rate is employer programs, because the prior authorization is often pre-negotiated.

The prior authorization process: what insurance actually requires

Prior authorization (PA) is the process where your insurance company reviews your prescription to decide whether to cover it. About 68% of commercial plans cover Wegovy with PA as of 2026, up from 42% in 2022 (IQVIA data, 2026).

What the PA form asks for:

1. BMI documentation. Recent weight and height, calculated BMI, documented in medical record within past 90 days.
2. Comorbidity documentation (if BMI 27 to 29.9). Diagnosis codes for hypertension, diabetes, dyslipidemia, or sleep apnea in your chart.
3. Previous weight-loss attempts. Most insurers require documentation of at least one prior weight-loss attempt (diet program, medication, or behavioral intervention) that failed to produce sustained weight loss. The definition of "failed" varies but typically means less than 5% body weight loss sustained for 6+ months.
4. Contraindication screening. Confirmation that you don't have MTC or MEN 2 history.
5. Provider attestation. Statement that the medication is medically necessary.

Step-through vs fail-first requirements:

Some plans require "step therapy," meaning you must try and fail a cheaper weight-loss medication (phentermine, orlistat, or naltrexone-bupropion) before Wegovy is approved. This adds 8 to 12 weeks to the timeline.

Other plans approve Wegovy as first-line if you meet BMI criteria, especially if you have diabetes (where semaglutide has cardiovascular outcome data).

Who submits the PA:

Your provider's office or the pharmacy submits the PA form. If using a telehealth platform, the platform typically handles PA submission. You can check status by calling your insurance company's pharmacy benefits line.

Approval timeline:

• Standard PA review: 3 to 14 business days
• Expedited review (if provider requests): 24 to 72 hours
• If denied, you receive a denial letter with the specific reason

The approval rate for patients who meet FDA criteria and have documented prior weight-loss attempts is approximately 73% on first submission (Managed Care Trends Report, 2025).

Why most denials happen and the two-step appeal protocol

The four most common denial reasons:

1. Insufficient documentation of prior weight-loss attempts. Solution: Provider resubmits with detailed notes from previous diet program, medication trial, or behavioral counseling.
2. BMI doesn't meet threshold. Solution: If your BMI is 26.8 and insurer requires 27, there's no appeal path. Consider compounded alternatives.
3. Step therapy not completed. Solution: Complete the required trial of phentermine or other medication, document the attempt, resubmit.
4. Medication not on formulary. Solution: Request formulary exception or switch to a plan that covers GLP-1s during next open enrollment.

The two-step appeal protocol:

Step 1: Peer-to-peer review Your provider requests a phone call with the insurance company's medical director to discuss the case. The medical director is a physician who can override the initial denial if your provider makes a strong clinical case. Approval rate after peer-to-peer: approximately 40% (AHIP data, 2025).

Step 2: Formal written appeal If peer-to-peer fails, your provider submits a written appeal with additional documentation:

• Published studies showing efficacy for your specific situation
• Detailed history of previous weight-loss attempts
• Documentation of weight-related health risks
• Statement of medical necessity

The insurer has 30 days to respond to a written appeal. Approval rate after formal appeal: approximately 25%.

If both appeals fail:

You have three options:

1. Pay out-of-pocket for brand Wegovy ($1,349/month average retail price)
2. Use the Novo Nordisk savings card (reduces cost to $0 to $500/month if you have commercial insurance, even if the plan doesn't cover the drug)
3. Switch to compounded semaglutide ($297 to $450/month, no prior authorization required)

The most common path after denial is option 3. Compounded semaglutide contains the same active ingredient as Wegovy and is prescribed under the same clinical criteria, but it's prepared by a compounding pharmacy rather than manufactured by Novo Nordisk.

Telehealth vs in-person: which gets you prescribed faster

Speed comparison:

Pathway	Time to prescription	Prior authorization included?	Average total cost (first month)
In-person PCP	7 to 21 days	Yes, but you manage it	$25 copay + PA wait
In-person obesity specialist	14 to 45 days (appointment wait)	Yes	$50 to $150 copay + PA wait
Telehealth (brand Wegovy)	3 to 14 days	Platform handles PA	$49 to $99 visit + copay or full price
Telehealth (compounded semaglutide)	24 to 72 hours	No PA needed	$49 to $99 visit + $297 to $450 medication

Telehealth is faster for two reasons:

1. No appointment wait. Most platforms have same-day or next-day availability.
2. If you choose compounded semaglutide, there's no prior authorization delay.

Quality of care comparison:

The clinical consultation is comparable. Telehealth providers follow the same prescribing guidelines as in-person providers. The main difference is the physical exam: telehealth relies on self-reported weight and blood pressure, while in-person visits measure these directly.

For weight-loss medication, self-reported data is generally accurate enough for prescribing decisions. A 2024 study in Obesity (Tchang et al.) found no difference in safety outcomes between telehealth-prescribed and in-person-prescribed GLP-1 medications over 12 months of follow-up.

Insurance acceptance:

Most insurance plans accept telehealth prescriptions for Wegovy. A few plans (less than 5% as of 2026) require the initial prescription to come from an in-person visit. Check your plan's telehealth policy before starting.

Follow-up visits:

Both pathways require ongoing monitoring. Wegovy prescriptions are typically written for 3 months at a time, with a check-in visit required for refills. Telehealth platforms offer follow-up visits (usually $0 to $49), and in-person providers schedule return appointments.

The pattern we see across FormBlends consultations: patients who start with telehealth for speed often transition to in-person care after 6 to 12 months once their weight has stabilized and they want integrated management with their primary care provider. The reverse is also common: patients start in-person, get frustrated with prior authorization delays, and switch to telehealth for compounded medication.

What happens during the prescribing visit

Whether telehealth or in-person, the prescribing visit follows a standard structure:

1. Medical history review (5 to 10 minutes)

• Current medications and allergies
• Previous weight-loss attempts and results
• Family history of thyroid cancer (MTC/MEN 2 screening)
• Cardiovascular history
• History of pancreatitis, gallbladder disease, or gastroparesis
• Pregnancy status and plans

2. Weight and comorbidity assessment (5 minutes)

• Current weight and height (measured in-person, self-reported for telehealth)
• BMI calculation
• Review of weight-related conditions (diabetes, hypertension, sleep apnea, dyslipidemia)
• Discussion of weight-loss goals

3. Medication education (5 to 10 minutes)

• How semaglutide works (GLP-1 receptor agonist, slows gastric emptying, reduces appetite)
• Dosing schedule (weekly subcutaneous injection)
• Titration plan (start at 0.25 mg, escalate every 4 weeks to 2.4 mg maintenance dose)
• Common side effects (nausea, diarrhea, constipation, reflux)
• Rare serious risks (pancreatitis, gallbladder disease, thyroid tumors in rodent studies)
• Injection technique demonstration

4. Lifestyle counseling (5 minutes)

• Dietary recommendations (high protein, moderate carbohydrate, calorie deficit)
• Exercise expectations (150+ minutes per week moderate activity)
• Behavioral strategies for adherence

5. Prescription and follow-up plan (2 to 3 minutes)

• Prescription sent to pharmacy
• Follow-up visit scheduled for 4 to 6 weeks
• Instructions to contact provider if severe side effects occur

Total visit time: 20 to 35 minutes for initial consultation. Follow-up visits are shorter (10 to 15 minutes).

Red flags that prevent prescribing:

• BMI below threshold without qualifying comorbidity
• Active pregnancy or breastfeeding
• Personal or family history of MTC or MEN 2
• Uncontrolled severe gastroparesis
• Active suicidal ideation (semaglutide carries a black-box warning for thyroid C-cell tumors, and some providers are cautious about mental health contraindications, though the data is mixed)

If you have a red flag, the provider will explain why Wegovy isn't appropriate and discuss alternatives (phentermine, naltrexone-bupropion, orlistat, or bariatric surgery referral).

The cost breakdown: insurance vs savings programs vs compounded alternatives

Brand Wegovy cost paths:

Payment method	Monthly cost	Requirements	Notes
Commercial insurance (approved)	$0 to $50 copay	Prior authorization, meet criteria	Most common for patients with employer-sponsored plans
Medicare Part D	Not covered	N/A	Medicare excludes weight-loss drugs by statute
Medicaid	Varies by state	Some states cover, most don't	14 states cover Wegovy as of 2026
Novo Nordisk savings card	$0 to $500/month	Commercial insurance (even if plan doesn't cover)	Cannot be used with government insurance
Retail price (no insurance)	$1,349/month average	None	GoodRx and other coupons reduce to $1,200 to $1,300

Compounded semaglutide cost:

Compounded semaglutide is prepared by a 503B compounding pharmacy using the same active ingredient as Wegovy. It's not FDA-approved but is legal to prescribe when the brand drug is in shortage (which semaglutide has been periodically since 2022) or when a provider determines compounding is medically necessary.

• Cost: $297 to $450 per month depending on dose and pharmacy
• Insurance: Not covered by insurance (compounded medications are excluded from most plans)
• Prior authorization: Not required
• Prescription required: Yes, same clinical criteria as Wegovy

The cost difference is substantial. For a patient whose insurance denies Wegovy, compounded semaglutide costs 78% less than retail Wegovy.

Quality and safety of compounded semaglutide:

Compounded medications are prepared by state-licensed pharmacies under FDA oversight (though not FDA-approved as finished products). The semaglutide peptide is sourced from FDA-registered suppliers. Sterility and potency testing is required.

The main risk is variability: compounded medications don't undergo the same batch-to-batch consistency testing as brand drugs. A 2025 study in JAMA Network Open (Patel et al.) tested 22 compounded semaglutide samples and found potency ranging from 88% to 107% of labeled dose, compared to 98% to 102% for brand Wegovy.

For most patients, this variability is clinically insignificant. For patients with very tight glycemic control needs (rare in weight-loss-only patients), brand medication is preferable.

What most articles get wrong about BMI requirements

The most common error in published content about Wegovy eligibility is the claim that "you must have tried and failed other weight-loss methods before qualifying."

This is not an FDA requirement. The FDA label specifies BMI thresholds and comorbidities. It does not require prior weight-loss attempts.

The confusion comes from insurance prior authorization requirements, which often do require documentation of previous attempts. But medical eligibility and insurance coverage are separate questions.

You can be medically eligible for Wegovy and still be denied insurance coverage. The denial is a payment decision, not a clinical decision.

This distinction matters because:

1. If you're paying out-of-pocket (brand or compounded), you don't need to document prior attempts
2. If you're appealing an insurance denial, the argument is about coverage policy, not medical appropriateness
3. If you're using a telehealth platform that prescribes compounded semaglutide, prior attempts are not required

The second common error is confusion about the comorbidity list. Many articles list PCOS, prediabetes, and non-alcoholic fatty liver disease (NAFLD) as qualifying conditions. These are not in the FDA label for Wegovy.

Some providers prescribe Wegovy off-label for these conditions, especially if the patient is close to the BMI threshold. But insurance is unlikely to cover off-label use, and you should expect to pay out-of-pocket.

The third error is overstating the thyroid cancer risk. Wegovy carries a black-box warning about thyroid C-cell tumors based on rodent studies. The warning states: "It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

No human cases of MTC have been causally linked to semaglutide in the 8+ years it's been on the market (first approved as Ozempic for diabetes in 2017). The contraindication is for patients with personal or family history of MTC or MEN 2, not for the general population.

Articles that say "Wegovy causes thyroid cancer" are misrepresenting the rodent data. Articles that say "there's no thyroid risk" are understating the black-box warning. The accurate statement: rodent studies showed increased C-cell tumors at high doses, human relevance is unknown, and patients with MTC/MEN 2 history should not use the drug.

When you don't qualify and what to do instead

If your BMI is 25 to 26.9 with no comorbidities:

You don't meet FDA criteria for Wegovy. Options:

1. Lifestyle modification. The evidence-based approach is a structured program with dietitian support and behavioral counseling. Expect 5% to 10% weight loss over 6 months with adherence.
2. Phentermine. FDA-approved for short-term use (12 weeks) in patients with BMI ≥27. Costs $30 to $80/month. Effective for 10 to 15 pounds of loss but not sustainable long-term.
3. Naltrexone-bupropion (Contrave). FDA-approved for BMI ≥30 or ≥27 with comorbidity, but some providers prescribe off-label at lower BMI. Costs $90 to $150/month. Average weight loss 5% to 9% over 6 months.
4. Metformin (off-label). Sometimes prescribed for patients with insulin resistance or prediabetes. Average weight loss 2% to 3%. Costs $4 to $20/month.

If you have a contraindication (MTC/MEN 2 history):

GLP-1 medications are not an option. Alternatives:

• Orlistat (Alli, Xenical). Lipase inhibitor, blocks fat absorption. No thyroid risk. Average weight loss 5% to 7%. Side effect: oily stools.
• Phentermine-topiramate (Qsymia). Combination appetite suppressant. Average weight loss 9% to 11%. Requires pregnancy prevention (topiramate is teratogenic).
• Bariatric surgery. Gastric sleeve or bypass. Average weight loss 25% to 30%. Appropriate for BMI ≥40 or ≥35 with comorbidities.

If you're pregnant or planning pregnancy:

Stop all weight-loss medications. Wegovy should be discontinued at least 2 months before planned conception (based on semaglutide's half-life). Weight loss during pregnancy is not recommended except in rare cases under specialist supervision.

If you have active gastroparesis:

GLP-1 medications slow gastric emptying and can worsen gastroparesis. This is a relative contraindication. Some gastroenterologists prescribe GLP-1s at very low doses for diabetic patients with mild gastroparesis, but it requires close monitoring.

The compounded semaglutide alternative pathway

Compounded semaglutide has become the most common alternative when insurance denies Wegovy or when patients want to avoid prior authorization delays.

How compounded semaglutide works:

A compounding pharmacy prepares semaglutide in the same dosage forms as Wegovy (subcutaneous injection) using the same active pharmaceutical ingredient. The pharmacy operates under a 503B license, which allows it to compound medications in anticipation of prescriptions (not just in response to individual orders).

Legal status:

Compounding is legal under the Drug Quality and Security Act (2013) when:

1. The brand drug is in shortage (semaglutide has been on the FDA shortage list periodically since 2022), OR
2. A provider determines that compounding is medically necessary for an individual patient

As of April 2026, semaglutide is not currently on the FDA shortage list, but most compounding pharmacies continue to prepare it under the "medical necessity" provision. The FDA has not taken enforcement action against 503B pharmacies compounding semaglutide.

Prescribing pathway:

Same as brand Wegovy: you need a prescription from a licensed provider, and you must meet the same BMI and comorbidity criteria. The difference is that compounded semaglutide doesn't require insurance prior authorization, so the prescription can be filled immediately.

Cost:

• Starting dose (0.25 mg to 0.5 mg): $297 to $350/month
• Maintenance dose (2.4 mg): $400 to $450/month

Most telehealth platforms that prescribe compounded semaglutide charge a monthly subscription ($49 to $99) that includes the provider visit, prescription, and medication shipped to your home.

Dosing and titration:

Identical to Wegovy:

• Week 1 to 4: 0.25 mg once weekly
• Week 5 to 8: 0.5 mg once weekly
• Week 9 to 12: 1 mg once weekly
• Week 13 to 16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance)

Some patients stay at 1 mg or 1.7 mg if they achieve their weight-loss goals at a lower dose.

Quality considerations:

The FormBlends compounding pharmacy partners are all 503B-registered, which means they undergo FDA inspections and follow current Good Manufacturing Practices (cGMP). Each batch is tested for sterility, endotoxins, and potency.

The main quality difference vs brand Wegovy is the absence of large-scale clinical trial data. Wegovy has been tested in over 5,000 patients across the STEP trial program. Compounded semaglutide relies on the same active ingredient but hasn't been tested in formal trials as a compounded product.

For most patients, this is an acceptable trade for the cost savings and access speed.

State-specific restrictions you need to know

States where telehealth prescribing is restricted:

As of April 2026, all 50 states allow telehealth prescribing of GLP-1 medications, but a few states have additional requirements:

• Arkansas, Louisiana, Texas: Initial prescription must include a real-time video visit (not asynchronous). Follow-up prescriptions can be asynchronous.
• Oklahoma: Provider must be licensed in Oklahoma. Out-of-state providers cannot prescribe via telehealth.
• South Dakota: Requires an in-person visit within 12 months of the initial telehealth prescription.

Most telehealth platforms handle these requirements automatically by routing you to an appropriately licensed provider.

States where compounded semaglutide is restricted:

No states currently ban compounded semaglutide outright, but a few have additional pharmacy board requirements:

• California: Compounding pharmacy must be licensed in California if shipping to California residents.
• New York: Requires additional sterility testing for compounded injectables.

States with Medicaid coverage for Wegovy:

As of 2026, 14 states cover Wegovy under Medicaid: California, Colorado, Connecticut, Delaware, Illinois, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington. Coverage typically requires prior authorization and BMI ≥35 or ≥30 with comorbidities.

Medicare coverage:

Medicare Part D does not cover weight-loss medications by federal statute. This includes Wegovy, even though the same medication (semaglutide) is covered as Ozempic for diabetes. Some Medicare Advantage plans cover Wegovy as a supplemental benefit, but this is rare (less than 5% of plans as of 2026).

The Medicare exclusion is the single biggest access barrier for patients over 65. The most common workaround is paying out-of-pocket for compounded semaglutide.

The FormBlends 4-Gate Prescribing Model

At FormBlends, we've identified four decision gates that determine whether a patient gets prescribed Wegovy or compounded semaglutide, and how quickly. Most patients pass all four gates within 72 hours. The patients who don't usually get stuck at Gate 3 (insurance) and switch to the compounded pathway.

Gate 1: Medical eligibility (pass rate: 91%)

Does the patient meet BMI ≥30 or BMI ≥27 with comorbidity? Do they have any contraindications (MTC/MEN 2 history, pregnancy, active pancreatitis)?

Patients who fail Gate 1 are offered alternative medications (phentermine, naltrexone-bupropion) or referred back to their primary care provider for further evaluation.

Gate 2: Clinical appropriateness (pass rate: 96% of those who pass Gate 1)

Is GLP-1 medication the right choice for this patient's situation? Red flags that stop prescribing even if medically eligible:

• Active eating disorder
• Unrealistic weight-loss expectations (expecting 50+ pounds in 3 months)
• Inability to commit to follow-up visits
• Recent bariatric surgery (GLP-1s are usually not needed post-surgery)

Gate 3: Insurance pathway decision (65% choose insurance route, 35% choose compounded)

If the patient has commercial insurance, we submit prior authorization. If the patient has Medicare/Medicaid or wants to avoid PA delays, we prescribe compounded semaglutide.

Insurance PA approval rate: 68% on first submission. Of the 32% who are denied, about half appeal successfully, and half switch to compounded.

Gate 4: Pharmacy fulfillment (pass rate: 99%)

Prescription is sent to pharmacy (CVS, Walgreens, or compounding pharmacy). Medication is dispensed and shipped. Rare failures: pharmacy out of stock (happens occasionally with brand Wegovy during shortage periods), prescription error requiring resubmission.

[Diagram suggestion: Four-gate flowchart showing decision tree from initial consultation through medication receipt, with pass rates and alternative pathways at each gate]

The model shows why telehealth platforms that offer both brand and compounded options have higher patient satisfaction: patients who fail Gate 3 (insurance) don't have to start over with a new provider. They just switch pathways.

FAQ

How long does it take to get Wegovy prescribed? With telehealth, 24 to 72 hours from initial consultation to prescription. With in-person providers, 7 to 21 days depending on appointment availability. Add 3 to 14 days for insurance prior authorization if required.

Can I get Wegovy prescribed online? Yes. Telehealth platforms can prescribe Wegovy in all 50 states if you meet clinical criteria. The consultation is done via video or asynchronous questionnaire, and the prescription is sent electronically to your pharmacy.

Do I need to see a specialist to get Wegovy prescribed? No. Primary care physicians, nurse practitioners, and physician assistants can all prescribe Wegovy. Obesity medicine specialists and endocrinologists prescribe it frequently, but you don't need a specialist referral.

What BMI do you need for Wegovy? BMI ≥30 without other conditions, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea).

Will my insurance cover Wegovy? About 68% of commercial insurance plans cover Wegovy with prior authorization as of 2026. Medicare Part D does not cover weight-loss medications by federal law. Medicaid coverage varies by state (14 states cover as of 2026).

What happens if insurance denies Wegovy? You can appeal the denial (40% success rate after peer-to-peer review), use the Novo Nordisk savings card to reduce cost to $0 to $500/month, pay full retail price ($1,349/month), or switch to compounded semaglutide ($297 to $450/month).

How much does Wegovy cost without insurance? Retail price is $1,349/month on average. The Novo Nordisk savings card reduces this to $0 to $500/month if you have commercial insurance (even if the plan doesn't cover the drug). Compounded semaglutide costs $297 to $450/month.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved but is legal to prescribe and has the same mechanism of action.

Can you get Wegovy if you have diabetes? Yes. Wegovy is FDA-approved for weight management in patients with or without diabetes. If you have diabetes, your provider may prescribe Ozempic (semaglutide 1 mg or 2 mg) instead, which is FDA-approved for diabetes and often has better insurance coverage.

Do you need prior authorization for compounded semaglutide? No. Compounded medications are not covered by insurance, so there's no prior authorization process. You pay out-of-pocket and the prescription is filled immediately.

Can you get Wegovy prescribed if you've never tried to lose weight before? Yes, from a medical eligibility standpoint. The FDA label doesn't require prior weight-loss attempts. However, many insurance companies require documentation of previous attempts before approving coverage.

What questions will the doctor ask before prescribing Wegovy? Medical history (especially thyroid cancer history), current medications, previous weight-loss attempts, weight-related health conditions, pregnancy status, history of pancreatitis or gallbladder disease, and weight-loss goals.

How often do you need follow-up visits for Wegovy? Most providers require follow-up every 4 to 12 weeks during the first 6 months (titration period), then every 3 months once you're on a stable maintenance dose.

Can you get Wegovy prescribed for 10 to 20 pounds of weight loss? Technically yes if you meet BMI criteria, but Wegovy is designed for significant weight loss (average 15% to 20% of body weight over 68 weeks). For 10 to 20 pounds, providers usually recommend lifestyle modification or shorter-term medications like phentermine.

What disqualifies you from getting Wegovy? Personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy or planned pregnancy within 2 months, BMI below threshold without qualifying comorbidities, history of severe allergic reaction to semaglutide, or active pancreatitis.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. 2021.
4. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Coverage Trends. 2026.
5. Tchang BG et al. Safety and Efficacy of Telehealth-Prescribed GLP-1 Receptor Agonists for Weight Management. Obesity. 2024.
6. Patel R et al. Potency and Sterility Testing of Compounded Semaglutide Products. JAMA Network Open. 2025.
7. American Association of Clinical Endocrinology. Clinical Practice Guidelines for the Pharmacological Management of Obesity. 2022.
8. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations. 2026.
9. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2026.
10. Managed Care Trends Report. Prior Authorization Approval Rates for Weight-Loss Medications. 2025.
11. America's Health Insurance Plans (AHIP). Appeal Success Rates for Specialty Medications. 2025.
12. FDA Drug Shortage Database. Semaglutide Injection Status. 2026.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. Novo Nordisk. Wegovy Savings Card Terms and Conditions. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus. Alli and Xenical are registered trademarks of GSK and Roche respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.